ISN World Congress of Nephrology will be live streaming “Late Breaking Clinical Trials” from WCN 2019. The purpose of the webcast is to give the worldwide nephrology community in-depth understanding of three major nephrology studies, including the CREDENCE study for which George Clinical plays a critical role.

Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation, the formal name of the CREDENCE Clinical Trial, is a comparative study of the efficacy and safety of canagliflozin versus placebo.  It has been concluded on the basis of a planned interim data analysis. CREDENCE is a randomized, double-blind, placebo controlled study involving multiple clinical centers enrolling approximately  4,400 patients with type 2 diabetes (T2D) with estimated glomerular filtration rate (eFGR) ≥ 30 to < 90 mL/min/1.73 m2, and albuminuria.

Register today HERE.